Caption Management’s Myriad Genetics MYGN Stock Holding History

Caption Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,300	Closed	-$216K	–	1432
2023 Q2	$216K	Buy	+9,300	New	+$203K	﹤0.01%	927
2020 Q1	–	Sell	-40,000	Closed	-$1.09M	–	994
2019 Q4	$1.09M	Sell	40,000 -22,000	-35%	-$605K	0.04%	485
2019 Q3	$1.78M	Buy	+62,000	New	+$1.81M	0.09%	264
2019 Q2	–	Sell	-100,000	Closed	-$3.32M	–	775
2019 Q1	$3.32M	Buy	+100,000	New	+$3.04M	0.18%	158

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caption Management's MYGN Position: Q1 2025 in Review

Caption Management sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 20,000 shares — an estimated $274K sold.

Caption Management first reported a position in MYGN in Q1 2019 and held it in 6 quarters. The position peaked at $1.97M in Q2 2023. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

Caption Management reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
Caption Management sold 20,000 Myriad Genetics shares in Q1 2025, an estimated $274K.
Caption Management first reported a position in Myriad Genetics in Q1 2019 and held it in 6 quarters.
Caption Management's Myriad Genetics position peaked at $1.97M in Q2 2023.
228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.